Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Wyeth Buy Rebuilds OTC Switch Potential

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's proposed $68 billion acquisition of Wyeth brings the return of a consumer health division and with it a pipeline structure for potential Rx-to-OTC switches

Related Content

Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
Pfizer Buys Ferrosan Consumer Unit, Expands In Russia And Northern Europe
Rx-to-OTC Switch Interest Explodes Following Deal Activity - Experts
Pfizer Plans To Give Diversified Businesses Time To Grow
Singulair Switch Among Merck's OTC Possibilities
Sales & Earnings In Brief
Switch Projected To Continue Driving OTC Market Growth In 5-Year Picture
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts